Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab plus Bevacizumab for Asymptomatic Brain Metastases in NSCLC
NCT04213170Phase 2Unknown
- Sponsor
- Sun Yat-sen University
- Start
- Apr 2019
- Primary completion
- Dec 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of sintilimab in non-small cell lung cancer (NSCLC), sponsored by Sun Yat-sen University. Status: unknown.
02
Drugs
sintilimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04213170.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04213170.